Cited by 377Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

The DOI matches its Crossref record; 922 of the 930 references it cites were found in a registry or an index.

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Groll, Andreas H., Piscitelli, Stephen C., Walsh, Thomas J.·1998·Advances in pharmacology

DOI 10.1016/s1054-3589(08)60129-5

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s1054-3589(08)60129-5

Cites

922 of 922 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–400 of 922

Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.
Lodge, J. K., Jackson-Machelski, E., Toffaletti, D. L., Perfect, J. R., & Gordon, J. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12008 · Cited by 170
Therapy of Cryptococcosis with a Combination of Flucytosine and Amphotericin B
Utz, J. P., Garriques, I. L., Sande, M. A., Warner, J. F., Mandell, G. L., McGehee, R. F., Duma, R. J., & Shadomy, S. (1975) · The Journal of Infectious Diseases · doi:10.1093/infdis/132.4.368 · Cited by 170
Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patients
Mills, W., Chopra, R., Linch, D. C., & Goldstone, A. H. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04825.x · Cited by 170
Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor [see comments]
Caspar, C. B., Seger, R., Burger, J., & Gmür, J. (1993) · Blood · doi:10.1182/blood.v81.11.2866.2866 · Cited by 170
Clinical Significance of Pseudallescheria boydii: A Review of 10 Years' Experience
Travis, L. B., Roberts, G. D., & Wilson, W. R. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60571-0 · Cited by 169
Fluconazole Penetration into Cerebrospinal Fluid: Implications for Treating Fungal Infections of the Central Nervous System
Arndt, C. A. S., Walsh, T. J., McCully, C. L., Balis, F. M., Pizzo, P. A., & Poplack, D. G. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/157.1.178 · Cited by 169
Prevention and Treatment of Pneumocystis Pneumonia
(1993) · New England Journal of Medicine · doi:10.1056/nejm199304153281524 · Cited by 169
Increased Gastric pH and the Bioavailability of Fluconazole and Ketoconazole
Blum, R. A., D'Andrea, D. T., Florentino, B. M., Wilton, J. H., Hilligoss, D. M., Gardner, M., Henry, E. B., Goldstein, H. R., & Schentag, J. J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-755 · Cited by 167
Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis
Gómez, F. J., Allendoerfer, R., & Deepe, G. S. (1995) · Infection and Immunity · doi:10.1128/iai.63.7.2587-2595.1995 · Cited by 166
An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis
Karp, J. E., Burch, P. A., & Merz, W. G. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80343-7 · Cited by 165
Itraconazole treatment of coccidioidomycosis
Graybill, J. R., Stevens, D. A., Galgiani, J. N., Dismukes, W. E., & Cloud, G. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90339-f · Cited by 164
Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function
Burgess, J. L., & Birchall, R. (1972) · The American Journal of Medicine · doi:10.1016/0002-9343(72)90117-9 · Cited by 164
Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar, J. G., Ringdén, O. T. H., Andersson, S., Sundberg, B., Ljungman, P. T., & Tydén, G. (1993) · PubMed · Cited by 162
Ketoconazole vs. Itraconazole for Antifungal Prophylaxis in Patients with Severe Granulocytopenia: Preliminary Results of Two Nonrandomized Studies
Thicot, G., Joosten, E., Boogaerts, M. A., Pitte, J. V., & Cauwenbergh, G. F. M. J. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s94 · Cited by 162
Two antifungal agents produced by a soil actinomycete.
Hazen, E. L., & Brown, R. (1950) · PubMed · Cited by 162
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
Schmatz, D. M., Romancheck, M. A., Pittarelli, L. A., Schwartz, R. E., Fromtling, R. A., Nollstadt, K. H., VanMiddlesworth, F. L., Wilson, K., & Turner, M. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5950 · Cited by 161
ACUTE RENAL TOXICITY WITH COMBINED USE OF AMPHOTERICIN B AND CYCLOSPORINE AFTER MARROW TRANSPLANTATION
Kennedy, M. S., Deeg, H. J., Siegel, M. B., Crowley, J. J., Storb, R. F., & Thomas, E. D. (1983) · Transplantation · doi:10.1097/00007890-198303000-00005 · Cited by 159
Amphotericin B lipid complex therapy of experimental fungal infections in mice
Clark, J. M., Whitney, R. R., Olsen, S., George, R. J., Swerdel, M. R., Kunselman, L., & BONNER, D. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.615 · Cited by 159
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis
TUCKER, R. M., Williams, P., Arathoon, E., Levine, B. E., Hartstein, A. I., Hanson, L. H., & Stevens, D. A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.3.369 · Cited by 159
Combined Therapy with Amphotericin B and 5-Fluorocytosine for Candida Meningitis
Smego, R. A., Perfect, J. R., & Durack, D. T. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.6.791 · Cited by 159
Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease
Mouy, R., Veber, F., Blanche, S., Donadieu, J., Brauner, R., Levron, J., Griscelli, C., & Fischer, A. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82023-2 · Cited by 158
Treatment of Blastomycosis and Histoplasmosis with Ketoconazole
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES MYCOSES STUDY GROUP (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-6-861 · Cited by 158
The emergence of fungi as major hospital pathogens
Bodey, G. P. (1988) · Journal of Hospital Infection · doi:10.1016/0195-6701(88)90220-4 · Cited by 157
Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study
Vertut‐Doï, A., Bolard, J., Chabbert, M., & Gary-Bobo, C. M. (1983) · Biochemistry · doi:10.1021/bi00281a024 · Cited by 156
Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis
Taylor, R. L., Williams, D. M., Craven, P. C., Graybill, J. R., Drutz, D. J., & Magee, W. E. (1982) · American Review of Respiratory Disease · doi:10.1164/arrd.1982.125.5.610 · Cited by 156
Evaluation of the Protective Efficacy of the Killed Coccidioides immitis Spherule Vaccine in Humans
Pappagianis, D., & the Valley Fever Vaccine Study Group (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.3.656 · Cited by 155
High-dose itraconazole in the treatment of severe mycoses
Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.707 · Cited by 155
Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections
Nemunaitis, J. J., Meyers, J. D., Buckner, C. D., Shannon‐Dorcy, K., Mori, M., Shulman, H. M., Bianco, J., Higano, C. S., Groves, E. S., & Storb, R. F. (1991) · Blood · doi:10.1182/blood.v78.4.907.907 · Cited by 155
The influence of gastric acidity on the bio-availability of ketoconazole
van der Meer, J. W. M., Keuning, J. J., Scheijgrond, H. W., Heykants, J. J. P., Cutsem, J. V., & Brugmans, J. P. (1980) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/6.4.552 · Cited by 154
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with twenty-one patients
Horsburgh, C. R., & Kirkpatrick, C. H. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90511-9 · Cited by 152
Treatment of sporotrichosis with itraconazole
Sharkey, P. K., Kauffman, C. A., Graybill, J. R., Stevens, D. A., Hostetler, J. S., Cloud, G., & Dismukes, W. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90280-3 · Cited by 152
Papulacandins, a new family of antibiotics with antifungal activity. I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E.
Traxler, P. M., Gruner, J., & Auden, J. A. L. (1977) · The Journal of Antibiotics · doi:10.7164/antibiotics.30.289 · Cited by 151
Bone Marrow Toxicity Associated with 5-Fluorocytosine Therapy
Kauffman, C. A., & Frame, P. T. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.2.244 · Cited by 151
Genetics and biochemistry of yeast multidrug resistance
Balzi, E., & Goffeau, A. (1994) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(94)90102-3 · Cited by 151
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
Murphy, M., Bernard, E. M., Ishimaru, T., & Armstrong, D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.696 · Cited by 151
Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity
Ahmad, I. N., Perkins, W. R., Lupan, D. M., Selsted, M. E., & Janoff, A. S. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00087-j · Cited by 150
IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans
Kawakami, K., Tohyama, M., Xie, Q.-M., & Saitô, A. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.14723.x · Cited by 150
Risk Factors for Fluconazole-Resistant Candidiasis in Human Immunodeficiency Virus-Infected Patients
Maenza, J. R., Keruly, J. C., Moore, R. D., Chaisson, R. E., Merz, W. G., & Gallant, J. E. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.219 · Cited by 150
KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS
Hann, I. M., Corringham, R. E., Keaney, M. G. L., Noone, P., Fox, J., Szawatkowski, M., Prentice, H. G., Blacklock, H. A., Shannon, M. S., Gascoigne, E. W., et al. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91874-8 · Cited by 150
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole
Chin, T. W., Loeb, M. B., & Fong, I. W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1671 · Cited by 149
Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
Devi, S. J. (1996) · Vaccine · doi:10.1016/0264-410x(95)00256-z · Cited by 148
Itraconazole Therapy for Chronic Coccidioidal Meningitis
TUCKER, R. M., Denning, D. W., Dupont, B., & Stevens, D. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-2-108 · Cited by 148
The Safety and Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Invasive Mycoses
Oppenheim, B. A., Herbrecht, R., & Kusne, S. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1145 · Cited by 148
Drug Interactions in Patients Infected with Human Immunodeficiency Virus
Piscitelli, S. C., Flexner, C. W., Minor, J. R., Polis, M. A., & Masur, H. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.4.685 · Cited by 148
Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections
Anaissie, E. J., Kontoyiannis, D. P., Huls, C. E., Vartivarian, S. E., Karl, C., Prince, R. A., Bosso, J. A., & Bodey, G. P. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.2.599 · Cited by 147
DISCOVERY, BIOSYNTHESIS, AND MECHANISM OF ACTION OF THE ZARAGOZIC ACIDS: Potent Inhibitors of Squalene Synthase
Bergstrom, J. D., Dufresne, C., Bills, G. F., Nallin-Omstead, M., & Byrne, K. M. (1995) · Annual Review of Microbiology · doi:10.1146/annurev.mi.49.100195.003135 · Cited by 145
Treatment of disseminated mycotic infections
Drutz, D. J., Spickard, A., Rogers, D. E., & Koenig, M. G. (1968) · The American Journal of Medicine · doi:10.1016/0002-9343(68)90075-2 · Cited by 144
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
Denning, D. W., Hanson, L. H., Perlman, A. M., & Stevens, D. A. (1992) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(92)90053-v · Cited by 144
Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant Recipients
Kramer, M. R., Marshall, S. E., Denning, D. W., KEOGH, A. M., TUCKER, R. M., Galgiani, J. N., Lewiston, N. J., Stevens, D. A., & Theodore, J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-4-327 · Cited by 143
Mode of Action of Clinically Important Antifungal Drugs
Kerridge, D. (1986) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60303-3 · Cited by 142
5-Fluorocytosine in the Treatment of Cryptococcal and Candida Mycoses
Fass, R. J., & PERKINS, R. L. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-4-535 · Cited by 142
Mode of action of 5-fluorocytosine
Diasio, R. B., Bennett, J. E., & Myers, C. E. (1978) · Biochemical Pharmacology · doi:10.1016/0006-2952(78)90507-5 · Cited by 141
Characterization of a novel, potent, and specific inhibitor of serine palmitoyltransferase.
Zweerink, M., EDISON, A. M., Wells, G. B., Pinto, W. J., & Lester, R. L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74001-0 · Cited by 139
Pharmacokinetics of fluconazole in pediatric patients
Brammer, K. W., & Coates, P. E. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974613 · Cited by 139
Fungal Sterols and the Mode of Action of the Polyene Antibiotics
Hamilton-Miller, J. M. T. (1974) · Advances in applied microbiology · doi:10.1016/s0065-2164(08)70556-2 · Cited by 138
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B
Mukherjee, J., Zuckier, L. S., Scharff, M. D., & Casadevall, A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.580 · Cited by 138
Clinical Aspects of Fungal Infection in Organ Transplant Recipients
Hibberd, P. L., & Rubin, R. H. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.supplement_1.s33 · Cited by 138
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis
Catanzaro, A., Galgiani, J. N., Levine, B. E., Sharkey, P. K., Fierer, J., Stevens, D. A., Chapman, S. W., & Cloud, G. A. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80371-4 · Cited by 137
Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B
Bolard, J., Seigneuret, M., & Boudet, G. (1980) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(80)90074-7 · Cited by 136
A Pan-American 5-Year Study of Fluconazole Therapy for Deep Mycoses in the Immunocompetent Host
Díaz, M. C., Negroni, R., Montero-Gei, F., Castro, L. G. M., Sampaio, S. A. P., Borelli, D., Restrepo, Á., Franco, L., Bran, J. L., Arathoon, E., et al. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s68 · Cited by 136
Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate
Ryder, N. S., Frank, I., & Dupont, M.-C. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.5.858 · Cited by 135
Nystatin-Resistant Mutants of Yeast: Alterations in Sterol Content
Woods, R. A. (1971) · Journal of Bacteriology · doi:10.1128/jb.108.1.69-73.1971 · Cited by 134
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134
Clinical efficacy and tolerability of terbinafine (Lamisil)-a new topical and systemic fungicidal drug for treatment of dermatomycoses
Villars, V. V., & Jones, T. C. (1989) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1989.tb00908.x · Cited by 134
Fatal Disseminated Candidiasis Due to Amphotericin-B-Resistant Candida guilliermondii
Dick, J. D., Rosengard, B. R., Merz, W. G., Stuart, R. K., Hutchins, G. M., & Saral, R. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-1-67 · Cited by 134
Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections
Sculier, J., Coune, A., Meunier, F., Brassinne, C., Laduron, C., Hollaert, C., Collette, N., Heymans, C., & Klastersky, J. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/s0277-5379(98)90033-5 · Cited by 134
Resistance to amphotericin B associated with defective sterol Î8â7isomerase in a Cryptococcus neoformans strain from an AIDS patient
Kelly, S. L., Lamb, D. C., Taylor, M., Corran, A. J., Baldwin, B. C., & Powderly, W. G. (1994) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1994.tb07140.x · Cited by 133
An Evaluation of Two Years of Clinical Experience with Ketoconazole
Symoens, J., Moens, M., Dom, J., Scheijgrond, H. W., Dony, J., Schuermans, V., Legendre, R., & Finestine, N. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.4.674 · Cited by 133
Patterns of Infection in Patients with Aplastic Anemia and the Emergence of Aspergillus As a Major Cause of Death
Weinberger, M., Elattar, I. A., Marshall, D., Steinberg, S. M., Redner, R. L., Young, N. S., & Pizzo, P. A. (1992) · Medicine · doi:10.1097/00005792-199201000-00003 · Cited by 132
Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections
Ng, T. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100129015 · Cited by 132
Itraconazole: Pharmacologic Studies in Animals and Humans
Cauteren, H. V., Heykants, J., Coster, R. D., & Cauwenbergh, G. F. M. J. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s43 · Cited by 131
Recent advances in the chemistry of anti-infective agents
Bentley, P. H., & Ponsford, R. J. (1993) · Medical Entomology and Zoology · Cited by 130
Pharmacology and toxicity of high-dose ketoconazole
Sugar, A. M., Alsip, S. G., Galgiani, J. N., Graybill, J. R., Dismukes, W. E., Cloud, G. A., Craven, P. C., & Stevens, D. A. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1874 · Cited by 129
Evidence for Conversion of 5-Fluorocytosine to 5-Fluorouracil in Humans: Possible Factor in 5-Fluorocytosine Clinical Toxicity
Diasio, R. B., Lakings, D. E., & Bennett, J. E. (1978) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.14.6.903 · Cited by 129
Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance
Block, E. R., BENNETT, J. E., LIVOTI, L. G., KLEIN, W. J., MacGREGOR, R. R., & HENDERSON, L. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-5-613 · Cited by 129
Effect of salt supplementation on amphotericin B nephrotoxicity
Llanos, A., Cieza, J. A., Bernardo, J., Echevarría, J., Biaggioni, I., Sabra, R., & Branch, R. A. (1991) · Kidney International · doi:10.1038/ki.1991.214 · Cited by 129
Identification of a Glucan-Associated Enolase as a Main Cell Wall Protein of Candida albicans and an Indirect Target of Lipopeptide Antimycotics
Angiolella, L., Facchin, M., Stringaro, A., Maras, B., Simonetti, N., & Cassone, A. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.3.684 · Cited by 129
Emerging Targets in Antibacterial and Antifungal Chemotherapy
Sutcliffe, J. A., & Georgopapadakou, N. H. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3274-3 · Cited by 128
The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid
Perfect, J. R., Toffaletti, D. L., & Rude, T. H. (1993) · Infection and Immunity · doi:10.1128/iai.61.10.4446-4451.1993 · Cited by 128
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
Perfect, J. R., Cox, G. M., Dodge, R. K., & Schell, W. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1910 · Cited by 128
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
Harris, B., Manning, B. W., Federle, T. W., & Diasio, R. B. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.1.44 · Cited by 128
Interleukin‐4 and ‐10 exacerbate candidiasis in mice
Tonnetti, L., Spaccapelo, R., Cenci, E., Mencacci, A., Puccetti, P., Coffman, R. L., Bistoni, F., & Romani, L. R. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250614 · Cited by 127
Pharmacokinetics of Amphotericin B in Infants and Children
Starke, J. R., Mason, E. O., Kramer, W. G., & Kaplan, S. L. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/155.4.766 · Cited by 126
Interaction of Ketoconazole with Rifampin and Isoniazid
Engelhard, D., Stutman, H. R., & Marks, M. I. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412273112606 · Cited by 126
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
Ruhnke, M., Schmidt‐Westhausen, A. M., & Trautmann, M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.575 · Cited by 126
Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice
Lopez‐Berestein, G., Hopfer, R. L., Mehta, R. T., Mehta, K., Hersh, E. M., & Juliano, R. L. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.2.278 · Cited by 125
Sphingofungins F and F: Novel serinepalmitoyl transferase inhibitors from Paecilomyces variotii.
Horn, W. S., Smith, J. L., Bills, G. F., Raghoobar, S. L., Helms, G. L., Kurtz, M. B., Marrinan, J. A., FROMMER, B. R., Thornton, R. A., & MANDALA, S. M. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1692 · Cited by 125
New antifungal antibiotics, benanomicins A and B from an Actinomycete.
TAKEUCHI, T., HARA, T., NAGANAWA, H., Okada, M., HAMADA, M., UMEZAWAT, H., Gomi, S., Sezaki, M., & Kondo, S. (1988) · The Journal of Antibiotics · doi:10.7164/antibiotics.41.807 · Cited by 125
Renal magnesium wasting associated with amphotericin B therapy
Barton, C. H., Pahl, M. V., Vaziri, N. D., & Cesario, T. C. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90106-2 · Cited by 125
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
Franzot, S. P., & Casadevall, A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.331 · Cited by 124
Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism
Schaffner, A., & Böhler, A. (1993) · Mycoses · doi:10.1111/j.1439-0507.1993.tb00732.x · Cited by 124
Azole Therapy for Trichosporonosis: Clinical Evaluation of Eight Patients, Experimental Therapy for Murine Infection, and Review
Anaissie, E. J., Gokaslan, A., Hachem, R. Y., Rubin, R., Griffin, G., Robinson, R. R., Sobel, J. D., & Bodey, G. P. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.5.781 · Cited by 124
Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
de Gans, J., Portegies, P., Tiessens, G., Schattenkerk, J. K. M. E., van Boxtel, C. J., Ketel, R. J. V., & Stam, J. (1992) · AIDS · doi:10.1097/00002030-199202000-00007 · Cited by 124
In-vitro studies with SF 86–327, a new orally active allylamine derivative
Shadomy, S., Espinel‐Ingroff, A., & Gebhart, R. J. (1985) · Medical Mycology · doi:10.1080/00362178585380201 · Cited by 124
Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers
Huang, Y. C., Colaizzi, J. L., Bierman, R. H., Woestenborghs, R., & Heykants, J. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.2.206 · Cited by 123
The Development Of Resistance By Candida Species To Polyene Antibiotics In Vitro
Athar, M. A., & Winner, H. I. (1971) · Journal of Medical Microbiology · doi:10.1099/00222615-4-4-505 · Cited by 123
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
Barry, A. L., & Brown, S. D. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1948 · Cited by 123
In Vivo Interferon- Therapy Augments the In Vitro Ability of Chronic Granulomatous Disease Neutrophils to Damage Aspergillus Hyphae
Rex, J. H., Bennett, J. E., Gallin, J. I., Malech, H. L., DeCarlo, E. S., & Melnick, D. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.4.849 · Cited by 123
Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities
Janoff, A. S., Perkins, W. R., Saletan, S., & Swenson, C. E. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150730 · Cited by 122
Fluconazole Penetration into Cerebrospinal Fluid in Humans
Foulds, G. H., Brennan, D. R., Wajszczuk, C. P., Catanzaro, A., Garg, D. C., Knopf, W. D., Rinaldi, M. G., & Weidler, D. J. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03159.x · Cited by 121
Effect of Prophylactic Fluconazole on the Frequency of Fungal Infections, Amphotericin B Use, and Health Care Costs in Patients Undergoing Intensive Chemotherapy for Hematologic Neoplasias
Schaffner, A., & Schaffner, M. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.4.1035 · Cited by 120
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
Lee, J. W., Seibel, N. L., Amantea, M., Whitcomb, P., Pizzo, P. A., & Walsh, T. J. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81975-4 · Cited by 120
Effect of fluconazole on the disposition of phenytoin
Blum, R. A., Wilton, J. H., Hilligoss, D. M., Gardner, M., Henry, E. B., Harrison, N. J., & Schentag, J. J. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.49 · Cited by 120
Comparison of the Efficacy of Amphotericin B and Fluconazole in the Treatment of Cryptococcosis in Human Immunodeficiency Virus-Negative Patients: Retrospective Analysis of 83 Cases
Dromer, F., Mathoulin, S., Dupont, B., Brugière, O., Letenneur, L., & French Cryptococcosis Study Group (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s154 · Cited by 120
Treatment of Systemic Fungal Infections With Liposomal Amphotericin B
Lopez‐Berestein, G. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390110097022 · Cited by 120
Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
Coker, R. J., Viviani, M. A., Gazzard, B., Pont, B. D., Pohle, H. D., Murphy, S. M., Atouguia, J., Champalimaud, J. L., & Harris, J. R. W. (1993) · AIDS · doi:10.1097/00002030-199306000-00011 · Cited by 119
Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities.
OKI, T., HIRANO, M., TOMATSU, K., Numata, K.-I., & Kamei, H. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.1756 · Cited by 119
Clinical pharmacokinetics of terbinafine (Lamisil)
Jensen, J. C. (1989) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1989.tb00904.x · Cited by 118
Lactate metabolism in patients with cancer
Waterhouse, C. (1974) · Cancer · doi:10.1002/1097-0142(197401)33:1 · Cited by 118
Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neotropenic patients
Moreau, P., Milpied, N. J., Fayette, N., Ramée, J., & Harousseau, J. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/30.4.535 · Cited by 118
Role of Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant Therapy for Fungal Infection in Patients with Cancer
Bodey, G. P., Anaissie, E. J., Gutterman, J. U., & Vadhan‐Raj, S. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.705 · Cited by 118
Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano, R. L., Grant, C. W. M., Barber, K. R., & Kalp, M. A. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10311-8 · Cited by 118
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
Fielding, R. M., Smith, P. C., Wang, L. H., Porter, J., & Guo, L. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1208 · Cited by 117
Miconazole
Heel, R. C., Brogden, R. N., Pakes, G. E., Speight, T. M., & Avery, G. S. (1980) · Drugs · doi:10.2165/00003495-198019010-00002 · Cited by 117
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
Hata, K., Kimura, J., Miki, H., Toyosawa, T., Nakamura, T., & Katsu, K. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2237 · Cited by 117
Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections after Marrow Transplant
Bowden, R. A., Cays, M., Gooley, T. A., Mamelok, R. D., & van Burik, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Increased Fluconazole Resistance of Cryptococcus neoformans Isolated from a Patient with AIDS and Recurrent Meningitis
Paugam, A., Dupouy‐Camet, J., Blanche, P., Gangneux, J., Tourte-Schaefer, C., & Sicard, D. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.5.975-a · Cited by 117
Some aspects of the absorption, distribution, and excretion of amphotericin B in man.
Db, L. (1958) · PubMed · Cited by 117
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
Mukherjee, J., Pirofski, L., Scharff, M. D., & Casadevall, A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3636 · Cited by 116
Combination Therapy of Experimental Candidiasis, Cryptococcosis, Aspergillosis and Wangiellosis in Mice
Polak, A. (2009) · Chemotherapy · doi:10.1159/000238524 · Cited by 116
Correlation between In Vitro and In Vivo Activity of Antifungal Agents against Candida Species
Anaissie, E. J., Karyotakis, N. C., Hachem, R., Dignani, M. C., & Rex, J. H. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.2.384 · Cited by 116
Mutation in cytochrome P-450-dependent 14α-demethylase results in decreased affinity for azole antifungals
BOSSCHE, H. V., Marichal, P., Gorrens, J., Bellens, D., Moereels, H., & Janssen, P. A. J. (1990) · Biochemical Society Transactions · doi:10.1042/bst0180056 · Cited by 114
Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats.
Sawaya, B. P., Weihprecht, H., Campbell, W. R., Lorenz, J. N., Webb, R. C., Briggs, J. P., & Schnermann, J. B. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115240 · Cited by 113
Synthesis and Antifungal Activity of Novel Cationic Pneumocandin Bo Derivatives
Bouffard, F. A., Zambias, R. A., Dropinski, J. F., Balkovec, J. M., Hammond, M. L., Abruzzo, G. K., Bartizal, K. F., Marrinan, J. A., & Kurtz, M. B. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00028a003 · Cited by 113
A Review of Complications of Amphotericin-B Therapy: Recommendations for Prevention and Management
Maddux, M. S., & Barriere, S. L. (1980) · Annals of Pharmacotherapy · doi:10.1177/106002808001400303 · Cited by 113
In Vitro Studies with 5-Fluorocytosine
Shadomy, S. (1969) · Applied Microbiology · doi:10.1128/aem.17.6.871-877.1969 · Cited by 112
WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.
IWAMOTO, T., Fujie, A., Sakamoto, K., TSURUMI, Y., Shigematsu, N., Yamashita, M., HASHIMOTO, S., OKUHARA, M., & KOHSAKA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.1084 · Cited by 111
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs
Fielding, R. M., Singer, A. W., Wang, L. H., Babbar, S., & Guo, L. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.299 · Cited by 110
The Release of Potassium Ions from Candida albicans in the Presence of Polyene Antibiotics
Gale, E. F. (1974) · Journal of General Microbiology · doi:10.1099/00221287-80-2-451 · Cited by 110
Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study
Esterre, P., INZAN, C. K., Ramarcel, E. R., Andriantsimahavandy, A., Ratsioharana, M., Pecarrere, J. L., & ROIG, P. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb15658.x · Cited by 110
Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs
Guo, L. S. S., Fielding, R. M., Lasiç, D. D., Hamilton, R. L., & Mufson, D. (1991) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(91)90249-n · Cited by 110
Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
Arning, M., Kliche, K. O., Heer‐Sonderhoff, A. H., & Wehmeier, A. (1995) · Mycoses · doi:10.1111/j.1439-0507.1995.tb00020.x · Cited by 110
Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
Martin, M. V., Yates, J. O., & Hitchcock, C. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.13 · Cited by 110
Fungicidal activity of cecropin A
DeLucca, A. J., Bland, J. M., Jacks, T. J., Grimm, C. C., Cleveland, T. E., & Walsh, T. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.481 · Cited by 109
Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870
Pfaller, M. A., Messer, S. A., & Coffmann, S. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.5.1094-1097.1995 · Cited by 109
Oral Treatment of Paracoccidioidomycosis and Histoplasmosis with Itraconazole in Humans
Negroni, R., Palmieri, O. J., Koren, F., Tiraboschi, I. N., & Galimberti, R. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s47 · Cited by 109
Flucytosine kinetics in subjects with normal and impaired renal function
Cutler, R. E., Blair, A. D., & Kelly, M. R. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978243333 · Cited by 109
A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase
Rocque, W. J., McWherter, C. A., Wood, D. C., & Gordon, J. I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82159-7 · Cited by 108
Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
Böhme, A., Ganser, A., & Hoelzer, D. T. (1995) · Annals of Hematology · doi:10.1007/bf01697985 · Cited by 108
In vitro and in vivo anti-Candida activity and toxicology of LY121019.
Gordee, R. S., Zeckner, D. J., Ellis, L. F., Thakkar, A. L., & Howard, L. C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1054 · Cited by 108
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits
Perfect, J. R., & Durack, D. T. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/16.1.81 · Cited by 107
Fungal Peritonitis in Patients on Peritoneal Dialysis
Michel, C., Courdavault, L., Khayat, R., Viron, B. M., Roux, P., & Mignon, F. (1994) · American Journal of Nephrology · doi:10.1159/000168699 · Cited by 107
The Future of Antifungal Therapy
Graybill, J. R. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s166 · Cited by 107
Mycoses in AIDS patients
Dupont, B., Denning, D. W., Marriott, D. J. E., Sugar, A. M., Viviani, M. A., & Sirisanthana, T. (1994) · Medical Mycology · doi:10.1080/02681219480000731 · Cited by 106
Lipid composition and polyene antibiotic resistance of Candida albicans mutants
Pierce, A. M., Pierce, H. D., Jr., Unrau, A. M., & Oehlschlager, A. C. (1978) · Canadian Journal of Biochemistry · doi:10.1139/o78-023 · Cited by 106
Evidence for a Common Transport System for Cytosine, Adenine and Hypoxanthine in Saccharomyces cerevisiae and Candida albicans
Polak, A., & Grenson, M. (1973) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1973.tb02608.x · Cited by 105
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
Gehrt, A., Peter, J., Pizzo, P. A., & Walsh, T. J. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.5.1302-1307.1995 · Cited by 105
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet, P., Garry, I., Charlier, N., Caillot, D., Kisterman, J. P., D'Athis, M., & Portier, H. (1992) · BMJ · doi:10.1136/bmj.305.6859.921 · Cited by 104
Itraconazole Affects Single‐Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics
Honig, P. K., Wortham, D. C., Hull, R. W., Zamani, K., Smith, J. E., & Cantilena, L. R. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03920.x · Cited by 104
Pharmacokinetic Studies on the Oral Antimycotic Agent 5-Fluorocytosine in Individuals with Normal and Impaired Kidney Function
Schönebeck, J., Polak, A., Fernex, M., & Scholer, H. J. (2009) · Chemotherapy · doi:10.1159/000221279 · Cited by 104
Treatment of paracoccidioidomycosis with itraconazole
Naranjo, M. S., Trujillo, M., Múnera, M. I., Restrepo, P., Gómez, I., & Restrepo, Á. (1990) · Medical Mycology · doi:10.1080/02681219080000091 · Cited by 104
Overview of the use of terbinafine (Lamisil®) in children
Jones, T. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb00711.x · Cited by 103
An Emulsion Formulation of Amphotericin B Improves the Therapeutic Index When Treating Systemic Murine Candidiasis
Kirsh, R. L., Goldstein, R., Tarloff, J. B., Parris, D., Hook, J., Hanna, N., Bugelski, P. J., & Poste, G. H. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.5.1065 · Cited by 103
A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies
Ninane, J. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974614 · Cited by 103
Azole resistance inCandida albicans
Smith, K. J., Warnock, D. W., Kennedy, C., Johnson, E. M., Hopwood, V., Cutsem, J. V., & BOSSCHE, H. V. (1986) · Medical Mycology · doi:10.1080/02681218680000201 · Cited by 103
Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
Anaissie, E. J., Paetznick, V. L., Proffitt, R. T., Adler‐Moore, J., & Bodey, G. P. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01975823 · Cited by 102
Induction of Prostaglandin Synthesis as the Mechanism Responsible for the Chills and Fever Produced by Infusing Amphotericin B
Gigliotti, F., Shenep, J. L., Lott, L., & Thornton, D. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/156.5.784 · Cited by 102
Pharmacological Studies with 5-Fluorocytosine
Block, E. R., & Bennett, J. E. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.1.6.476 · Cited by 101
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
Oakley, K. L., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1124 · Cited by 101
In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.
Chin, N. X., Weitzman, I., & Della-Latta, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.850 · Cited by 101
Yeast in the Urine: Solutions for a Budding Problem
Fisher, J. F., Newman, C. L., & Sobel, J. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.183 · Cited by 101
Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice
Gondal, J. A., Swartz, R. P., & Rahman, A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1544 · Cited by 101
A Subcutaneous Reservoir for Intrathecal Therapy of Fungal Meningitis
Diamond, R. D., & Bennett, J. E. (1973) · New England Journal of Medicine · doi:10.1056/nejm197301252880405 · Cited by 101
Is there a role for GPIs in yeast cell-wall assembly?
de Nobel, H., & Lipke, P. N. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90003-5 · Cited by 100
Special features of the clinical use of oral terbinafine in the treatment of fungal diseases
Villars, V. V., & Jones, T. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb00013.x · Cited by 100
L-671,329, a new antifungal agent. I. Fermentation and isolation.
SCHWARTZ, R. E., GIACOBBE, R. A., Bland, J. A., & Monaghan, R. L. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.163 · Cited by 100
Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis Model
Stiller, R. L., Bennett, J. E., Scholer, H. J., Wall, M., Polak, A., & Stevens, D. A. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.6.1070 · Cited by 100
Influence of food on the pharmacokinetics of ketoconazole
Daneshmend, T. K., Warnock, D. W., Ene, M., Johnson, E. M., Potten, M. R., Richardson, M. D., & Williamson, P. J. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.1 · Cited by 99
Defect in urinary acidification induced in vitro by amphotericin B
Steinmetz, P. R., & Lawson, L. R. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106270 · Cited by 99
Sphingofungins A,B,C, and d; a new family of antifungal agents. I. Fermentation, isolation, and biological activity.
VanMiddlesworth, F. L., GIACOBBE, R. A., LOPEZ, M., Garrity, G. M., Bland, J. A., Bartizal, K. F., Fromtling, R. A., Polishook, J. D., Zweerink, M., Edison, A. M., et al. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.861 · Cited by 99
Pradimicins A, B and C: New antifungal antibiotics. II. In vitro and in vivo biological activities.
OKI, T., Tenmyo, O., HIRANO, M., TOMATSU, K., & Kamei, H. (1990) · The Journal of Antibiotics · doi:10.7164/antibiotics.43.763 · Cited by 98
Amorolfine
Haria, M., & Bryson, H. M. (1995) · Drugs · doi:10.2165/00003495-199549010-00008 · Cited by 98
Effect of Fluconazole on Zidovudine Pharmacokinetics in Patients Infected with Human Immunodeficiency Virus
Sahai, J. V., Gallicano, K., Pakuts, A. P., & Cameron, D. W. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.5.1103 · Cited by 98
Candida Endocarditis Treated with 5-Fluorocytosine
Record, C. O., Skinner, J. M., Sleight, P., & Speller, D. C. E. (1971) · BMJ · doi:10.1136/bmj.1.5743.262 · Cited by 97
Use of Fluconazole in the Treatment of Candidal Endophthalmitis
Akler, M. E., Vellend, H., McNeely, D. M., Walmsley, S. L., & Gold, W. L. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.3.657 · Cited by 97
Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb00001.x · Cited by 96
Structure of aureobasidin A.
IKAI, K., Takesako, K., Shiomi, K., MORIGUCHI, M., UMEDA, Y., Yamamoto, J., Kato, I., & NAGANAWA, H. (1991) · The Journal of Antibiotics · doi:10.7164/antibiotics.44.925 · Cited by 96
WATER EXCRETION IN POTASSIUM-DEFICIENT MAN*
Rubini, M. E. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104448 · Cited by 96
Interleukin-12 regulation of host defenses against Coccidioides immitis
Magee, D. M., & Cox, R. A. (1996) · Infection and Immunity · doi:10.1128/iai.64.9.3609-3613.1996 · Cited by 96
Itraconazole: pharmacology, clinical experience and future development
De Beule, K. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00043-7 · Cited by 96
In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis
Sugar, A. M., & Liu, X. P. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1314 · Cited by 96
The pharmacokinetics of itraconazole in animals and man: an overview
Heykants, J., Michiels, M., Meuldermans, W., Monbaliu, J. G., Lavrijsen, K., Peer, A. V., Levron, J. C., Woestenborghs, R., & Cauwenbergh, G. F. M. J. (1987) · Cited by 96
Altered Tissue Distribution of Amphotericin B by Liposomal Encapsulation: Comparison of Normal Mice to Mice Infected with Candida albicans
Lopez‐Berestein, G., Rosenblum, M. G., & Mehta, R. T. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.199 · Cited by 95
EVALUATION OF THE DRUG INTERACTION BETWEEN INTRAVENOUS HIGH-DOSE FLUCONAZOLE AND CYCLOSPORINE OR TACROLIMUS IN BONE MARROW TRANSPLANT PATIENTS
Osowski, C. L., Dix, S. P., Lin, L. S., Mullins, R. E., Geller, R. B., & Wingard, J. R. (1996) · Transplantation · doi:10.1097/00007890-199604270-00026 · Cited by 95
Hepatic injury associated with itraconazole
Lavrijsen, A. P. M., Balmus, K. J., Nugteren‐Huying, W. M., Roldaan, A. C., Wout, J. W. V., & Stricker, B. H. C. (1992) · The Lancet · doi:10.1016/0140-6736(92)90527-a · Cited by 95
Evaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic Patients
Hughes, W. T., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, C. D., & Young, L. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.supplement_1.s206 · Cited by 95
Impairment of Neutrophil Antifungal Activity against Hyphae of Aspergillus fumigatus in Children Infected with Human Immunodeficiency Virus
Roilides, E., Holmes, A. H., Blake, C., Pizzo, P. A., & Walsh, T. J. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.4.905 · Cited by 95
High-Dose Fluconazole Therapy for Cryptococcal Meningitis in Patients with AIDS
Menichetti, F., Fiorio, M., Tosti, A., Gatti, G., Pasticci, M. B., Miletich, F., Marroni, M., Bassetti, D., & Pauluzzi, S. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.838 · Cited by 94
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Walsh, T. J., Gonzalez, C., Lyman, C. A., Chanock, S. J., & Pizzo, P. A. (1996) · PubMed · Cited by 93
Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers
Kan, V. L., Bennett, J. E., Amantea, M., Smolskis, M. C., McManus, E., Grasela, D. M., & Sherman, J. W. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.418 · Cited by 93
Treatment of Experimental Invasive Aspergillosis with Novel Amphotericin B/Cholesterol-Sulfate Complexes
Patterson, T. F., Miniter, P., Dijkstra, J., Szoka, F. C., Ryan, J. L., & Andriole, V. T. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.4.717 · Cited by 93
Modulation of Host Defenses by Cytokines: Evolving Adjuncts in Prevention and Treatment of Serious Infections in Immunocompromised Hosts
Roilides, E., & Pizzo, P. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.508 · Cited by 93
Polyoxin D inhibits growth of zoopathogenic fungi
Becker, J. M., Covert, N. L., Shenbagamurthi, P., Steinfeld, A. S., & Naider, F. R. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.6.926 · Cited by 93
Ketoconazole therapy of progressive coccidioidomycosis
Galgiani, J. N., Stevens, D. A., Graybill, J. R., Dismukes, W. E., & Cloud, G. A. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90143-x · Cited by 92
Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
Prentice, A., Warnock, D. W., Johnson, S. A., Phillips, M. J., & Oliver, D. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.2.247 · Cited by 92
Cryptococcal Intracerebral Mass Lesions
Fujita, N. K., REYNARD, M., SAPICO, F. L., GUZE, L. B., & EDWARDS, J. E. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-3-382 · Cited by 92
Treatment of Blastomycosis with Fluconazole: A Pilot Study
Pappas, P. G., Bradsher, R. W., Chapman, S. W., Kauffman, C. A., Dine, A., Cloud, G. A., & Dismukes, W. E. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.2.267 · Cited by 92
Cure of Murine Candidiasis by Recombinant Soluble Interleukin-4 Receptor
Puccetti, P., Mencacci, A., Cenci, E., Spaccapelo, R., Mosci, P., Enssle, K.-H., Romani, L. R., & Bistoni, F. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.6.1325 · Cited by 92
Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
George, D., Miniter, P., & Andriole, V. T. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.1.86 · Cited by 92
Empiric Therapy with Amphotericin B in Febrile Granulocytopenic Patients
Walsh, T. J., Lee, J. D., Lecciones, J., Rubin, M., BUTLER, K. M., Francis, P., Weinberger, M., Roilides, E., Marshall, D., Gress, J., et al. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.3.496 · Cited by 92

Research works printed but not linked: 18

Atkinson, 1969, Pharmacokinetics of intrathecal administered amphotericin B., Am. Rev. Respir. Dis., 99, 917
Benhamu, 1991, Does ketoconazole prevent fungal infection in children treated with high-dose chemotherapy and bone-marrow transplantation?, Bone Marrow Transplant., 7, 127
Bernardo, 1994, The effect of L-arginine on amphotericin B-induced nephrotoxicity., J. Am. Soc. Nephrol., 5, 917
Brammer, 1987, A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man, 141
Feldman, 1992, The use of granulocyte-stimulating factor (GCSF) enhanced granulocyte transfusions from normal donors in patients with neutropenia related fungal infections, Blood, 80, 414a
G. Gaenger, G. Just-Nuebling, M. Eichel, R. Hoika, W. Stille (1993). Itraconazole solution in patients with non-response to fluconazole. In Abstracts of the IXth International Conference on AIDS, abstract 1394.
Gascoigne, 1981, The kinetics of ketoconazole in animals and man., Clin. Res. Rev., 1, 177
Gelfand, 1988, Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1., Clin. Res., 36, 456
Graybill, 1982, Ketoconazole therapy for systemic fungal infections: Inadequacy of standard dose regimens., Am. Rev. Respir. Dis., 126, 171
Gupta, 1994, Antifungal agents: An overview. Part II., J. Am. Acad. Dermatol., 30, 911, 10.1016/S0190-9622(94)70112-1 · DOI
Hiemenz, 1995, Emergency use of amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis historical control comparison with amphotericin B, Blood, 86, 849a
Jolidon, 1993, 2,3 oxidosqualene-lanosterol cyclase, an attractive target for antifungal drug design.
Moore, 1995, Hematopoietic reconstitution: New approaches., Clin. Cancer Res., 1, 3
Peeters, 1986, Itraconzole, a new orally active triazole derivative for treatment of vaginal candidosis., Curr. Ther. Res., 39, 496
Plempel, 1988, Antimycotic effects of BAY R 3783 in vitro and on dermatophytoses and opportunistic mycoses of the organs in vivo, Rev. lb. Micol., 5, 0
Ringden, 1993, Clinical experience with AmBisome with special emphasis on experience with children., Bone Marrow Transplant., 12, S149
Schaude, 1988, Biological activity of SDZ 89485 in animal models., Rev. lb. Micol., 5, P51
Shepard, 1986, Cyclosporin-ketoconazole: A potentially dangerous drug interaction., Clin. Pharmacol., 6, 468

Sorted by citations

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Self-citation
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Zygomycosis in a Tertiary‐Care Cancer Center in the Era of Aspergillus‐ Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent Cases
Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H. M., Champlin, R. E., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674

See all 377

Authors: Groll, A. H., Piscitelli, S. C., & Walsh, T. J.
Affiliations: National Institutes of Health (US)
ORCID: Groll, Andreas H.
Piscitelli, Stephen C.
Walsh, Thomas J.
Venue: Advances in pharmacology
Publisher: Elsevier
Published: 1998
Volume: 44
Pages: 343-500
ISSN: 1054-3589 (ISSN-L)
DOI: 10.1016/s1054-3589(08)60129-5
OpenAlex: W63281979
Cited by: 377
References: 930
Citations by year: 2026: 3 · 2025: 3 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 8 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 13 · 2015: 13 · 2014: 16 · 2013: 13 · 2012: 7
FWCI: 54.29
Type: book chapter
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advances in pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords: systemic antifungal agents, clinical pharmacology, antifungal drug development, antifungal drug targets, fungal infection
MeSH terms: Animals, Antifungal Agents, Fungi, Humans, Mycoses, Triazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks